Tuberculosis Screening and Diagnosis in People with HIV

TO THE EDITOR: Cain et al. (Feb. 25 issue)¹ conclude that screening for tuberculosis in people with human immunodeficiency virus (HIV) infection should include questions about a combination of symptoms rather than just chronic cough. They suggest that the recently published World Health Organization (WHO) approach² for the diagnosis of tuberculosis among people with HIV has a sensitivity of less than 33%. However, they restrict the WHO approach to the diagnosis of pulmonary tuberculosis and do not consider extrapulmonary tuberculosis. For extrapulmonary tuberculosis, the WHO recommends taking into account other characteristics, such as weight loss, fever, and night sweats. We agree, however, that the use of the three screening criteria (cough of any duration, fever of any duration, and night sweats lasting 3 or more weeks in the preceding 4 weeks) proposed by Cain et al. simplifies the screening and diagnosis of pulmonary and extrapulmonary tuberculosis and will facilitate the implementation of screening and diagnosis at the country level.

Olivier Koole, M.D.
Johan van Griensven, M.D., Ph.D.
Robert Colebunders, M.D., Ph.D.
Institute of Tropical Medicine
Antwerp, Belgium
okoole@itg.be

Since publication of their article, the authors report no further potential conflict of interest.


THE AUTHORS REPLY: Koole and colleagues note that our analysis of the WHO approach to tuberculosis screening in people with HIV did not address extrapulmonary tuberculosis. The WHO has guidelines for the diagnosis of extrapulmonary tuberculosis but no explicit guidelines regarding screening.¹ The guidelines include several symptoms that might prompt a clinician to consider extrapulmonary tuberculosis, but there is no explicit recommendation to screen for them in all patients or to trigger a diagnostic evaluation for tuberculosis when one of them is present. Chronic cough is the only symptom explicitly noted for routine tuberculosis screening.¹

We reported on symptom screening when patients with all types of tuberculosis were included. We analyzed the data again after excluding the 25 patients who had only extrapulmonary tuberculosis. The sensitivity of cough lasting 2 to 3 weeks

No potential conflict of interest relevant to this letter was reported.

Prophylactic Platelet Transfusions

TO THE EDITOR: Slichter et al. (Feb. 18 issue)1 report on the results of the platelet-dose (PLADO) trial (ClinicalTrials.gov number, NCT00128713). To interpret the results of this study accurately, it would be very important to know the ABO compatibility between recipients and platelet transfusions. A major ABO incompatibility can decrease the response to a platelet transfusion by between 23% and 41% in patients with hematologic cancers.2 A platelet transfusion with minor ABO incompatibility is also associated with a decrease in the post-transfusion increment, perhaps because of immune complexes.3 Others have also reported that ABO compatibility is associated with an increase in the recovery at 1 hour but not at 24 hours.4 Moreover, a previous meta-analysis of studies that examined the effect of the transfusion platelet dose on several variables showed that when the studies that guaranteed ABO compatibility of the platelet transfusions were combined, high doses of platelets were associated with a significant increase in the post-transfusion increment as compared with low doses of platelets (weighted mean difference, 23.6×10^9 platelets per liter; 95% confidence interval, 18.28×10^9 to 28.92×10^9 per liter; P<0.001).5

Joan Cid, M.D.
Ginés Escolar, M.D.
Miguel Lozano, M.D.
Hospital Clínic
Barcelona, Spain
jcid.hj23.ics@gen.cat

No potential conflict of interest relevant to this letter was reported.


TO THE EDITOR: Slichter et al. report that at doses between 1.1×10^11 and 4.4×10^11 platelets per square meter, the number of platelets in the prophylactic transfusion had no effect on the incidence of bleeding in hospitalized patients undergoing hematopoietic stem-cell transplantation or chemotherapy for hematologic cancers or solid tumors. Although the authors accounted for some confounders (e.g., serum fibrinogen, activated partial-thromboplastin time, prothrombin time, and acute promyelocytic leukemia), they did not account for other relevant risk factors for bleeding, such as mucosal or vascular infiltration by solid tumors, chemotherapy-induced gastrointestinal mucositis, graft-versus-host disease,1 hemorrhagic cystitis,2 and veno-occlusive disease after allogeneic hematopoietic stem-cell transplantation.3

Finally, although they did not directly account for bleeding events, the number of required platelet transfusions could be related to post-transfusion increments, which are known to be higher when platelets are stored for less than 6 days.4

Daniele Focosi, M.D.
University of Pisa
Pisa, Italy
dfocosi@tin.it

Kevin P. Cain, M.D.
Charles M. Heilig, Ph.D.
Jay K. Varma, M.D.
Centers for Disease Control and Prevention
Atlanta, GA
kcain@cdc.gov

Since publication of their article, the authors report no further potential conflict of interest.